Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
作者信息
Fricke Jeremy, Wang Joshua, Gallego Natalie, Mambetsariev Isa, Kim Pauline, Babikian Razmig, Chen Bihong T, Afkhami Michelle, Subbiah Vivek, Salgia Ravi
机构信息
Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA.
Columbia University, New York, NY.
出版信息
Clin Lung Cancer. 2023 Nov;24(7):666-671. doi: 10.1016/j.cllc.2023.08.006. Epub 2023 Aug 6.
Abstract
摘要
相似文献
1
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.塞尔帕替尼和普拉替尼在RET重排肺腺癌中诱发乳糜性腹水：病例系列
Clin Lung Cancer. 2023 Nov;24(7):666-671. doi: 10.1016/j.cllc.2023.08.006. Epub 2023 Aug 6.
2
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.患者为 RET 重排非小细胞肺癌，在接受普拉替尼相关肺炎和颅内失败后，用塞普替尼成功治疗。
Anticancer Drugs. 2024 Jul 1;35(6):559-562. doi: 10.1097/CAD.0000000000001590. Epub 2024 Mar 8.
3
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.普拉替尼治疗 RET 重排的晚期非小细胞肺癌（NSCLC）患者的临床证据和不良事件管理更新。
Crit Rev Oncol Hematol. 2024 Feb;194:104243. doi: 10.1016/j.critrevonc.2023.104243. Epub 2023 Dec 20.
4
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.简要报告：RET 酪氨酸激酶抑制剂治疗期间的乳糜性胸腔积液和乳糜性腹水。
J Thorac Oncol. 2022 Sep;17(9):1130-1136. doi: 10.1016/j.jtho.2022.06.008. Epub 2022 Jul 2.
5
Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC.乳糜性腹水作为塞尔帕替尼治疗RET阳性非小细胞肺癌可能的罕见副作用
J Thorac Oncol. 2023 Feb;18(2):e11-e13. doi: 10.1016/j.jtho.2022.10.012.
6
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.非关键 RET 突变介导的获得性对塞尔帕替尼和普拉替尼耐药的结构基础。
Ann Oncol. 2021 Feb;32(2):261-268. doi: 10.1016/j.annonc.2020.10.599. Epub 2020 Nov 5.
7
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.RET 融合阳性非小细胞肺癌中对选择性 RET 酪氨酸激酶抑制剂耐药的机制。
Ann Oncol. 2020 Dec;31(12):1725-1733. doi: 10.1016/j.annonc.2020.09.015. Epub 2020 Sep 29.
8
Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report.普拉替尼治疗肺腺癌多种融合：病例报告。
J Int Med Res. 2022 Jun;50(6):3000605221105368. doi: 10.1177/03000605221105368.
9
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with alterations.将普拉替尼纳入美国医疗计划处方集用于治疗伴有特定改变的非小细胞肺癌和甲状腺癌的预算影响。
J Manag Care Spec Pharm. 2022 Feb;28(2):218-231. doi: 10.18553/jmcp.2021.21308. Epub 2021 Nov 2.
10
Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.塞尔帕替尼用于治疗具有RET基因突变或融合的肺癌和甲状腺癌。
Drugs Today (Barc). 2021 Oct;57(10):621-629. doi: 10.1358/dot.2021.57.10.3313852.
引用本文的文献
1
Case report: Selpercatinib in the treatment of fusion-positive advanced lung adenocarcinoma: a challenging clinical case.病例报告：塞尔帕替尼治疗融合阳性晚期肺腺癌：一例具有挑战性的临床病例。
Front Oncol. 2025 Jan 15;14:1500449. doi: 10.3389/fonc.2024.1500449. eCollection 2024.
2
Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database.塞尔帕替尼的不良事件概况：基于FAERS数据库的真实世界药物警戒分析
BMC Cancer. 2024 Dec 3;24(1):1486. doi: 10.1186/s12885-024-13250-1.
3
Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time.塞尔帕替尼用于转染期间重排（RET）激活的晚期实体瘤的长期安全性：LIBRETTO-001研究中不良事件随时间的不同模式
Oncologist. 2024 Dec 6;29(12):1068-1078. doi: 10.1093/oncolo/oyae282.
4
Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series.胰腺腺泡细胞癌的分子与临床特征：一项单机构病例系列研究
Cancers (Basel). 2024 Oct 9;16(19):3421. doi: 10.3390/cancers16193421.
5
Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.普拉替尼与塞尔帕替尼之间不良事件特征差异：一项基于美国食品药品监督管理局不良事件报告系统的真实世界研究
Front Pharmacol. 2024 Sep 20;15:1424980. doi: 10.3389/fphar.2024.1424980. eCollection 2024.
6
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".携带RET基因融合的非小细胞肺癌（NSCLCs）：从发现到新型强效选择性RET抑制剂的出现——“阴影与迷雾”
Cancers (Basel). 2024 Aug 19;16(16):2877. doi: 10.3390/cancers16162877.
7
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.RET 抑制剂在 RET 融合阳性肺癌中的应用：过去、现在和未来。
Drugs. 2024 Sep;84(9):1035-1053. doi: 10.1007/s40265-024-02040-5. Epub 2024 Jul 13.
8
Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for -Rearranged NSCLC-A Case Report.阿来替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌期间自发性双侧乳糜胸的发生——一例报告
JTO Clin Res Rep. 2023 Nov 17;4(12):100606. doi: 10.1016/j.jtocrr.2023.100606. eCollection 2023 Dec.
本文引用的文献
1
Chylothorax and chylous ascites: Overview, management, and nutrition.乳糜胸和乳糜腹水：概述、处理和营养。
Nutr Clin Pract. 2023 Jun;38(3):557-563. doi: 10.1002/ncp.10973. Epub 2023 Mar 20.
2
Ascites During Selpercatinib Treatment: Need for a Multidisciplinary Approach.塞尔帕替尼治疗期间的腹水：多学科方法的必要性
J Thorac Oncol. 2023 Feb;18(2):e9-e10. doi: 10.1016/j.jtho.2022.09.229.
3
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.RET 异常致癌与 RET 抑制剂治疗：现状与未来展望。
Pharmacol Ther. 2023 Feb;242:108344. doi: 10.1016/j.pharmthera.2023.108344. Epub 2023 Jan 9.
5
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib.接受塞普替尼治疗的晚期甲状腺髓样癌患者的乳糜性胸腔积液。
Eur J Endocrinol. 2022 Nov 29;187(6):905-915. doi: 10.1530/EJE-22-0643. Print 2022 Dec 1.
6
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.RET 重排与非小细胞肺癌：不断演变的治疗格局与未来挑战。
Biochim Biophys Acta Rev Cancer. 2022 Nov;1877(6):188810. doi: 10.1016/j.bbcan.2022.188810. Epub 2022 Oct 4.
7
Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.达沙替尼引起的乳糜胸：一种常见不良事件的罕见表现——一例病例报告并文献复习
EJHaem. 2021 May 18;2(3):545-550. doi: 10.1002/jha2.226. eCollection 2021 Aug.
8
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.简要报告：RET 酪氨酸激酶抑制剂治疗期间的乳糜性胸腔积液和乳糜性腹水。
J Thorac Oncol. 2022 Sep;17(9):1130-1136. doi: 10.1016/j.jtho.2022.06.008. Epub 2022 Jul 2.
9
Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.塞普替尼治疗 RET 突变型甲状腺癌与胃肠道不良事件相关。
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3824-e3829. doi: 10.1210/clinem/dgac337.
10
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients.实体转移性泛癌患者体细胞突变的评估
Cancers (Basel). 2021 Jun 3;13(11):2776. doi: 10.3390/cancers13112776.
Zotero 插件